Effect of letrozole cotreatment in progestin-primed ovarian stimulation on IVF/ICSI outcomes in POSEIDON group 3 and 4 poor responders: a retrospective cohort study
These findings indicate that advanced-aged poor ovarian response patients may benefit more from using letrozole as an advantageous adjuvant agent in the progestin-primed ovarian stimulation protocol to obtain more oocytes and embryos in clinical practice. Trial registration This trial was retrospectively registered.
Authors
- Lei Jin (ORCID: https://orcid.org/0000-0002-9052-4590)
- Yifan Chu (ORCID: https://orcid.org/0000-0002-3128-3117)
- Chen Jiayun
- Luyao Wang (ORCID: https://orcid.org/0000-0001-6470-5059)
- Yue Jing (ORCID: https://orcid.org/0000-0002-0273-3481)
- Jiaxin Xie
Institutions
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1186/s40001-025-02393-x
- Citations
- 2
- Primary Topic
- Ovarian function and disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.40
Funders
- Peking University
- Peking University Third Hospital
- National Key Research and Development Program of China